Open main menu - A Hematology Oncology Wiki β

Non-small cell lung cancer, KRAS-mutated

Page editor Section editor
Amit Kulkarni.jpg
Amit Kulkarni, MBBS
University of Minnesota
Minneapolis, MN

Travis Osterman, DO, MS
Vanderbilt University
Nashville, TN


Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

1 regimens on this page
1 variants on this page


Advanced or metastatic disease, subsequent lines of therapy

Docetaxel monotherapy

back to top


Study Evidence Comparator Comparative Efficacy
Blumenschein et al. 2015 (GSK 114653) Randomized Phase II (C) Trametinib Did not meet primary endpoint of PFS
Jänne et al. 2017 (SELECT-1) Phase III (C) Docetaxel & Selumetinib Did not meet primary endpoint of PFS


Supportive medications

21-day cycles


  1. GSK 114653: Blumenschein GR Jr, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Jänne PA. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2015 May;26(5):894-901. Epub 2015 Feb 26. link to original article link to PMC article contains verified protocol PubMed
  2. SELECT-1: Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial. JAMA. 2017 May 9;317(18):1844-1853. link to original article contains verified protocol PubMed